Skip to main content

Table 1 Analysis of clinical data

From: Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-β1 levels in serum of patients with atrial fibrillation

  SR + CHD SR + VHD PaAF + VHD PeAF + VHD
Patient number 10 30 30 30
Sex, M/F (n) 4/6 16/14 13/17 12/18
Age (years) 16.20 ± 3.31 54.75 ± 3.68 55.61 ± 6.83 53.58 ± 4.63
Preoperative data     
Heart rate (beats/min) 102.4 ± 4.51 79 ± 6.00 81 ± 7.00 83 ± 9.20
NYHA class I/II/III/IV 2/7/1/0 0/12/10/8 0/7/13/10 0/5/12/13
Echocardiographic parameters     
LVDd 34 ± 2.30 53.55 ± 8.70 55.66 ± 14.13 54.97 ± 12.36
LVDs 24 ± 3.11 36.38 ± 1.26 39 ± 10.22 34.13 ± 11.03
EF (%) 64 ± 4.12 55.01 ± 4.80 53.08 ± 5.32 52.21 ± 5.21
LAD (mm) 23 ± 6.73 47.25 ± 5.19c 55.43 ± 6.80a,c 59.23 ± 5.92b,c
RAD (mm) 27 ± 8.71 38.40 ± 5.20 38.10 ± 4.64 38.20 ± 5.00
Preoperative length of stay 10.00 ± 9.36 15.00 ± 1.80 16.00 ± 11.53 16.00 ± 13.40
Valve disease     
Pure MVD 0 12 15 12
Mitral stenosis   4 5 6
Mitral regurgitation   5 6 2
Mitral stenoregurgitation   3 4 4
Pure AVD 0 10 6 5
Aortic valve stenosis   6 3 1
Aortic valve regurgitation   4 3 4
DVD 0 8 9 13
Preoperative drug     
Digitalis 0 18 28 30
Diuretic 4 22 24 28
Nitrate drug 0 26 23 27
Calcium channel blocker 0 10 12 11
β-blocker 3 10 22 30
ACEI 0 19 21 18
Operative data     
Surgical procedure     
MVR/AVR/DVR 0/0/0 12/10/8 15/6/9 12/5/13
CPB duration 78 ± 11.44 130 ± 12.42 141 ± 23.44 145 ± 13.23
Aortic clamp time 45.32 ± 33.32 79 ± 34.43 82 ± 35.26 90 ± 42.13
  1. Data are presented as n or mean ± standard deviation.
  2. AVD, aortic valve disease; CHD, Congenital heart disease; DVD, Double valvular disease (mitral and aortic valves); MVD, Mitral valvular disease; PaAF, Paroxysmal atrial fibrillation; PeAF, Persistent atrial fibrillation; SR, Sinus rhythm; VHD, Valvular heart disease.
  3. aPaAF + VHD vs. SR + VHD; P < 0.01. bPeAF + VHD vs. SR + VHD; P < 0.01. cLAD vs. RAD; P < 0.01.